Shlapatska Lm
National Academy of Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shlapatska Lm.
Immunology and Cell Biology | 2010
Mariya Yurchenko; Kovalevska Lm; Shlapatska Lm; Ganna G. Berdova; Edward A. Clark; Svetlana P. Sidorenko
The CD150 receptor is expressed on thymocytes, activated and memory T cells, B cells, platelets, natural killer T cells, and mature dendritic cells, and is also detected on tumor cells of Hodgkins lymphoma (HL) and diffuse large B‐cell lymphoma with an activated B cell phenotype. Here, we report that the level of CD150 expression is elevated during B cell differentiation toward plasma cells. In primary tonsillar B cells and HL cell lines, CD150 signaling regulates the phosphorylation of three types of mitogen‐activated protein kinases (MAPKs): extracellular signal‐regulated kinase 1/2 (ERK1/2), p38 MAPK, and Jun N‐terminal kinase 1/2 (JNK1/2). CD150 induced ERK1/2 activation in primary tonsillar B cells and in two HL cell lines. CD150 mediated activation of JNK1/2 p54 and JNK2‐γ kinase isoforms in all CD150+ B cell lines we tested. CD150 associated with the serine/threonine kinase hematopoetic progenitor kinase 1 (HPK1) regardless of CD150 tyrosine phosphorylation or binding of the SH2D1A adaptor protein to CD150, and HPK1 overexpression enhanced CD150‐mediated JNK1/2 phosphorylation. CD150 ligation inhibited cell proliferation of all studied HL cell lines and induced apoptosis in L1236 HL cells that did not depend on JNK activity. As signaling through CD150 modulates MAPK activity in HL tumor cells, CD150 may contribute to regulation of tumor cell maintenance in low‐rate proliferating HLs.
PLOS ONE | 2015
Alexander M. Najakshin; Mariya Yurchenko; Tatyana Malysheva; Kovalevska Lm; Shlapatska Lm; Yuriy A. Zozulya; Alexander V. Taranin; Branka Horvat; Sidorenko Sp
CD150 (IPO3/SLAM) belongs to the SLAM family of receptors and serves as a major entry receptor for measles virus. CD150 is expressed on normal and malignant cells of the immune system. However, little is known about its expression outside the hematopoietic system, especially tumors of the central nervous system (CNS). Although CD150 was not found in different regions of normal brain tissues, our immunohistochemical study revealed its expression in 77.6% of human CNS tumors, including glioblastoma, anaplastic astrocytoma, diffuse astrocytoma, ependymoma, and others. CD150 was detected in the cytoplasm, but not on the cell surface of glioma cell lines, and it was colocalized with the endoplasmic reticulum and Golgi complex markers. In addition to the full length mRNA of the mCD150 splice isoform, in glioma cells we found a highly expressed novel CD150 transcript (nCD150), containing an 83 bp insert. The insert is derived from a previously unrecognized exon designated Cyt-new, which is located 510 bp downstream of the transmembrane region exon, and is a specific feature of primate SLAMF1. Both mCD150 and nCD150 cDNA variants did not contain any mutations and had the leader sequence. The nCD150 transcript was also detected in normal and malignant B lymphocytes, primary T cells, dendritic cells and macrophages; however, in glioma cells nCD150 was found to be the predominant CD150 isoform. Similarly to mCD150, cell surface expression of nCD150 allows wild type measles virus entry to the cell. Our data indicate that CD150 expression in CNS tumors can be considered a new diagnostic marker and potential target for novel therapeutic approaches.
Clinical Immunology | 2018
Inna Gordiienko; Shlapatska Lm; Kovalevska Lm; Svetlana P. Sidorenko
SLAMF1/CD150 receptor is a founder of signaling lymphocyte activation molecule (SLAM) family of cell-surface receptors. It is widely expressed on cells within hematopoietic system. In hematologic malignancies CD150 cell surface expression is restricted to cutaneous T-cell lymphomas, few types of B-cell non-Hodgkins lymphoma, near half of cases of chronic lymphocytic leukemia, Hodgkins lymphoma, and multiple myeloma. Differential expression among various types of hematological malignancies allows considering CD150 as diagnostical and potential prognostic marker. Moreover, CD150 may be a target for antibody-based or measles virus oncolytic therapy. Due to CD150 signaling properties it is involved in regulation of malignant cell fate decision and tumor microenvironment in Hodgkins lymphoma and chronic lymphocytic leukemia. This review summarizes evidence for the important role of CD150 in pathogenesis of hematologic malignancies.
PLOS ONE | 2017
Inna Gordiienko; Shlapatska Lm; Valeriia Kholodniuk; Lilia Sklyarenko; Daniel F. Gluzman; Edward A. Clark; Svetlana P. Sidorenko
Cell surface expression of CD150 and CD180 receptors in chronic lymphocytic leukemia (CLL) associates with mutational IGHV status and favourable prognosis. Here we show a direct correlation between cell surface expression and colocalization of these receptors on CLL B cells. In the absence of CD150 and CD180 on the cell surface both receptors were expressed in the cytoplasm. The CD150 receptor was colocalized with markers of the endoplasmic reticulum, the Golgi apparatus and early endosomes. In contrast, CD180 was detected preferentially in early endosomes. Analysis of CD150 isoforms differential expression revealed that regardless of CD150 cell surface expression the mCD150 isoform with two ITSM signaling motifs was a predominant CD150 isoform in CLL B cells. The majority of CLL cases had significantly elevated expression level of the soluble sCD150, moreover CLL B cells secrete this isoform. CD150 or CD180 crosslinking on CLL B cells alone led to activation of Akt, mTORC1, ERK1/2, p38MAPK and JNK1/2 networks. Both CD150 and CD180 target the translation machinery through mTOR independent as well as mTOR dependent pathways. Moreover, both these receptors transmit pro-survival signals via Akt-mediated inhibition of GSK3β and FOXO1/FOXO3a. Unexpectedly, coligation CD150 and CD180 receptors on CLL B cells led to mutual inhibition of the Akt and MAPK pathways. While CD150 and CD180 coligation resulted in reduced phosphorylation of Akt, ERK1/2, c-Jun, RSK, p70S6K, S6RP, and 4E-BP; it led to complete blocking of mTOR and p38MAPK phosphorylation. At the same time coligation of CD150 and CD40 receptors did not result in Akt and MAPK inhibition. This suggests that combination of signals via CD150 and CD180 leads to blocking of pro-survival pathways that may be a restraining factor for neoplastic CLL B cells propagation in more than 50% of CLL cases where these receptors are coexpressed.
Blood | 2004
Svitlana V. Mikhalap; Shlapatska Lm; Olga V. Yurchenko; Maria Y. Yurchenko; Ganna G. Berdova; Kim E. Nichols; Edward A. Clark; Svetlana P. Sidorenko
Experimental Oncology | 2011
Shabelnik My; Kovalevska Lm; Mariya Yurchenko; Shlapatska Lm; Rzepetsky Y; Sidorenko Sp
Experimental Oncology | 2012
Mariya Yurchenko; Shlapatska Lm; Sidorenko Sp
Experimental Oncology | 2011
Mariya Yurchenko; Shlapatska Lm; O.L. Romanets; D. Ganshevskiy; Elena Kashuba; A. Zamoshnikova; Yu.V. Ushenin; Boris Snopok; Sidorenko Sp
Experimental Oncology | 2004
Shlapatska Lm; Berdova Gg; Kovalevska Lm; Kulyk Gi; Klein G; Sidorenko Sp; Chekhun Vf
Experimental Oncology | 2014
Shlapatska Lm; Kovalevska Lm; Gordiienko Im; Sidorenko Sp